BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36855295)

  • 21. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
    Gu ZY; Dong YJ; Fu XR; Li NN; Liu Y; Wu XX; Wang YN; Li YH; Ren HY; Zhang MZ; Li XF; Wang MH; Wu YM; Liu DH; Wang Z; Hu LD; Huang WR
    Chin Med J (Engl); 2021 Jun; 134(13):1584-1592. PubMed ID: 34133361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
    Kambhampati S; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.
    Lee HG; Kim SY; Kim I; Kim YK; Kim JA; Kim YS; Lee HS; Park J; Kim SJ; Shim H; Eom HS; Park BB; Lee J; Park SK; Cheong JW; Park KW
    Blood Res; 2015 Sep; 50(3):160-6. PubMed ID: 26457283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
    Lu N; Li XF; Dong YJ; Wang YN; Fu XR; Wu YM; Li YH; Wang MH; Li NN; Ren HY; Wang Z; Zhang MZ; Wu XX; Hu LD; Liu Y; Huang WR
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):117-122. PubMed ID: 32135627
    [No Abstract]   [Full Text] [Related]  

  • 25. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
    Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma: a retrospective study].
    Lu XL; Li Y; Huang WR; Guo YL; Zhao XL; Lu N; Zhu HY; Wang QS; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):617-22. PubMed ID: 23815909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].
    Liang ZY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1033-7. PubMed ID: 23363798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
    Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH
    Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
    Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
    Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
    Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    González-Barca E; Boumendil A; Blaise D; Trněný M; Masszi T; Finel H; Michieli MG; Bittenbring JT; Gritti G; Snowden JA; Bishton M; Bruno B; de Villambrosia SG; Janikova A; Leleu X; Anagnostopoulos A; Poiré X; Crysandt M; Özkurt ZN; Vandenberghe E; Itälä-Remes M; Cahn JY; Jantunen E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A
    Bone Marrow Transplant; 2020 Feb; 55(2):393-399. PubMed ID: 31541205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma.
    Haeno T; Rai S; Miyake Y; Inoue M; Fujimoto K; Fujii A; Iwata Y; Minamoto S; Taniguchi T; Kakutani H; Inoue H; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Morita Y; Tanaka H; Tatsumi Y; Ashida T; Matsumura I
    J Clin Exp Hematop; 2023 Jun; 63(2):99-107. PubMed ID: 37121716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
    Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
    Othman T; Penaloza J; Zhang S; Daniel CE; Gaut D; Oliai C; Brem EA; Baweja A; Ly J; Reid J; Pinter-Brown L; Lee M; Abdulhaq H; Tuscano J
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e947-e957. PubMed ID: 35858904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
    Inano S; Iwasaki M; Iwamoto Y; Sueki Y; Fukunaga A; Yanagita S; Arima N
    Int J Hematol; 2014 Feb; 99(2):162-8. PubMed ID: 24338743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas].
    Wang QL; Huang HW; Jin ZM; Tang XW; Qiu HY; Fu CC; Han Y; Miao M; Chang HR; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):952-956. PubMed ID: 27995879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
    Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
    Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
    Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.